Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 6 08:13 ETSource: BioPharma Dive
From the source
Read at biopharmadive.comLilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
